Fig. 3.

The effect of tofacitinib (Tofa), dosed intracecally (IC; 1 mg/kg BID, with accompanying oral (PO) vehicle dosing) or PO (15 mg/kg BID, with accompanying IC vehicle dosing) on the disease activity index (a), and its components, body weight (b), stool consistency (c) and occult blood (d), following oxazolone (Oxa) challenge to sensitized mice. Each control mouse received both PO and IC vehicles. Data are expressed as the mean ± SEM (n = 10–35). * p = 0.03, ** p = 0.006, *** p = 0.0006, and **** p < 0.0001 vs. Veh/Veh (Student’s t-test), # p = 0.02–0.04, and ## p = 0.009 vs. Veh/Oxa (One-way ANOVA, Fisher’s LSD post-hoc test)